CX-072 In Patients With Advanced/recurrent Solid Tumours Or ...

HRA Health Research Authority Protecting and promoting the interests of patients and the public in health research. The Health Research Authority website uses essential cookies

This site uses session cookies and persistent cookies to improve the content and structure of the site.

By clicking “Accept All Cookies”, you agree to the storing of cookies on this device to enhance site navigation and content, analyse site usage, and assist in our marketing efforts.

By clicking 'See cookie policy' you can review and change your cookie preferences and enable the ones you agree to.

By dismissing this banner, you are rejecting all cookies and therefore we will not store any cookies on this device.

Accept all cookies See cookie policy Glossary Search glossary CX-072 in patients with advanced/recurrent solid tumours or lymphomas

• Research type

  Research Study

• Full title

  An open-label, dose-finding and proof of concept study of the PD-L1 probody therapeutic, CX-072, as monotherapy and in combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in subjects with advanced or recurrent solid tumours or lymphomas

• IRAS ID

  211188

• Contact name

  Hendrik-Tobias Arkenau

• Contact email

  [email protected]

• Sponsor organisation

  CytomX Therapeutics, Inc

• Eudract number

  2016-002490-36

• Clinicaltrials.gov Identifier

  128042, IND Number

• Duration of Study in the UK

  2 years, 3 months, 13 days

• Research summary

  Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue and organs. There are more than 200 types of cancer, including breast, lung, prostate, and lymphoma (cancer of the lymphatic system). Symptoms vary depending on the type. More than 1 in 3 people will develop some form of cancer during their lifetime.Surgery is the first treatment for most cancer, as solid tumours can usually be surgically removed. Other commonly used treatments are chemotherapy (powerful cancer-killing medication) or radiotherapy (high-energy X-rays). Immunotherapy has been used with some success, but is limited by side effects. There is unmet need for drugs that limit immune activation to the tumour to enable new or more effective combination therapies.CytomX Therapeutics, Inc. have developed a new drug, CX-072, that has been designed to act on the immune system protein PD-L1 at the tumour, but not in the rest of the body.This study is being done to evaluate the safety and tolerability of CX-072 when given alone or in combination with ipilimumab and vemurafenib (approved cancer therapies) in patients with metastatic or advanced unresectable solid tumours or lymphomas.This is a multicentre study which will take place across Europe and United States. It is anticipated that approximately 149 patients will be enrolled worldwide. Patients will be assigned to 1 of 5 parts of the study depending on the type of cancer they have and the time they begin treatment. Patients may receive intravenous (infusion directly into a vein) CX-072 on its own, CX-072 with ipilimumab, or CX-072 with oral vemurafenib. Treatment will be given either once every 2 or 3 weeks depending on the drug. Different doses of CX-072 will be given depending on results found in earlier stages of the study.

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  17/SC/0109

• Date of REC Opinion

  30 May 2017

• REC opinion

  Further Information Favourable Opinion

Stay up to date with latest news, updates to regulations and upcoming learning events Sign up to our newsletter © Copyright HRA 2025

• Contact us
• Privacy notice
• Terms & conditions
• Accessibility statement
• Feedback or concerns

Site by Big Blue Door